Description

Dusquetide (SGX942) TFA is a first-in-class innate defense regulator (IDR). Dusquetide TFA modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide TFA shows activity in both reducing inflammation and increasing clearance of bacterial infection[1]. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–Cancer-programmed cell death–C27H48F3N9O7—-[1]Kudrimoti M, et al. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016 Dec 10;239:115-125.—-667.72–98.49–C[C@@H](C(N)=O)NC([C@H]1N(C([C@H](C(C)C)NC([C@H]([C@@H](C)CC)NC([C@H](CCCNC(N)=N)N)=O)=O)=O)CCC1)=O.OC(C(F)(F)F)=O–Cancer; Infection–10 mM in DMSO–Bacterial;p62—-Anti-infection;Autophagy–Peptides